Gene test may guide chemo choice for tough pancreatic cancer

NCT ID NCT05475366

Recruiting now Knowledge-focused Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study aims to see if using five gene signatures from a patient's tumor can help doctors choose the best first chemotherapy for advanced pancreatic cancer. About 85 people with metastatic pancreatic cancer will have their tumor genes analyzed to pick between two standard chemo regimens. The main goal is to see if this personalized approach increases the number of patients whose tumors shrink significantly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy (FOLFIRINOX or Gem-nabP) chosen based on tumor gene signatures
What this could lead to: If successful, this could lead to a more personalized way to select chemotherapy for advanced pancreatic cancer, potentially improving how many patients respond to treatment.
What could go wrong: This is a small pilot study with only 85 participants, so results may not apply to everyone. The approach is experimental and may not improve outcomes or could be too complex for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, PANCREATIC DUCTAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Matthew-Wood syndrome pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, PANCREATIC DUCTAL PROGNOSIS

Contacts and locations

Locations

CHU Robert Debré
RECRUITING

Reims, 51092, France
Hôpital Beaujon
RECRUITING

Clichy, 92210, France
Hôpital Claude Hurriez
RECRUITING

Lille, 59037, France
Hôpital HENRI MONDOR
RECRUITING

Créteil, 94010, France
Hôpital PAUL BROUSSE 12 Avenue Paul Vaillant Couturier
RECRUITING

Villejuif, 94800, France
Institut Curie
RECRUITING

Saint-Cloud, 92210, France
Institut Paoli-Calmettes
RECRUITING

Marseille, 13573, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.